Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Dilawri Cardiovascular Institute
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Blood, Heart and Circulation

Blood, Heart and Circulation

Recruiting

Putting Heart Failure Patient's Experiences at the Centre of Home Health Monitoring Design

We hope to understand a heart failure patient's journey during the transition of care from the emergency department or hospital to home. We also want to explore how technology, like home health monitoring, can better support patients' recovery during this time.

Recruitment Poster

Status
Recruiting
Principal Investigator
Chad Kim Sing
Body Locations and Systems
Heart Failure
Area
Vancouver
Age
all ages

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs. 

Status
Recruiting
Principal Investigator
Jerry Chen
Body Locations and Systems
Peripheral Arterial Disease
Area
Vancouver
Age
50 and above

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event).

Status
Recruiting
Principal Investigator
Anthony Fung
Body Locations and Systems
Arteries
Area
Vancouver
Age
45 and above

Evaluating coronary artery disease screening for kidney transplant candidates

The purpose of this study is to determine if coronary artery disease (CAD) screening is necessary for patients on the waiting list for kidney transplantation. Patients on the waiting list for kidney transplantation are at risk for CAD. Currently, patients without any symptoms of CAD undergo annual testing to determine if they have disease. The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown.

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Blood, Heart and Circulation
Coronary Artery Disease
Kidneys and Urinary System
Area
Vancouver
Age
18 and above

A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma (ADAM)

This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a prospective, cohort study of 24 participants with multiple myeloma, in whom a lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible participants will initiate thromboprophylaxis with apixaban prior to starting their DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and plasma drug concentration will be measured.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood
Area
Vancouver
Age
19 and above

Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)

The purpose of this project is to conduct a proof of concept study in patients with probable Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker compared to an Angiotensin Converting Enzyme inhibitor (ACEI).

recruitment poster

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
High Blood Pressure
Alzheimer's Disease
Area
Vancouver
Age
50 and above

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI). The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.

Recruitment Poster

Status
Recruiting
Principal Investigator
Andrei Krassioukov
Body Locations and Systems
High Blood Pressure
Spinal Cord Injury
Area
Vancouver
Age
18-55

Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED (RAFF-2)

Atrial fibrillation (AF) and atrial flutter (AFL) are cardiac rhythm problems where there is an irregular, rapid heart rate. Investigators plan to study Emergency Department (ED) patients with recent-onset episodes of AF or AFL (RAFF) where rapid heart rate requires urgent treatment to restore normal heart rhythm. RAFF is the most common rhythm disorder managed in the ED. Investigators recently showed that doctors use a wide variety of treatment approaches in Canadian EDs for RAFF.

Status
Recruiting
Principal Investigator
Corinne Hohl
Body Locations and Systems
Atrial Fibrillation
Arrhythmia
Area
Vancouver
Age
16 and above

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)

This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial for patients presenting within 12 hours of their symptom onset. Patients will be randomized to TNK-tPA or standard of care.

Status
Recruiting
Principal Investigator
Thalia Field
Body Locations and Systems
Stroke
Stroke
Area
Vancouver
Age
18 and above

The CREST-2 Registry (C2R)

The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists' eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease.

Status
Recruiting
Principal Investigator
Philip A. Teal
Body Locations and Systems
Coronary Artery Disease
Area
Vancouver
Age
18-80

Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome (SAHaRA Pilot)

The purpose of this study is to determine the feasibility of conducting a large trial examining the effect on clinical outcome of a liberal red blood cell (RBC) transfusion strategy compared to a restrictive strategy (usual care) in patients with aneurysmal subarachnoid hemorrhage (SAH)

Status
Recruiting
Principal Investigator
Donald Griesdale
Body Locations and Systems
Aneurysm
Blood Transfusion and Donation
Area
Vancouver
Age
18 and above

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF)

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

Status
Recruiting
Principal Investigator
Anthony Fung
Body Locations and Systems
Stroke
Atrial Fibrillation
Area
Vancouver
Age
30-60

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction (REFINE-ICD)

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack in the prior year, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

Status
Recruiting
Principal Investigator
Matthew Bennett
Body Locations and Systems
Heart Attack
Area
Vancouver
Age
18-80

Dabigatran Following Transient Ischemic Attack and Minor Stroke (DATAS II)

Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. It has been suggested that this agent may provide the superior benefits of anticoagulation in acute stroke, without the concomitant increase in hemorrhage risk associated with heparin/LMWH or warfarin.

Status
Recruiting
Principal Investigator
Thalia Field
Body Locations and Systems
Stroke
Area
Vancouver
Age
18 and above

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients. In 20% of patients however, the disease is either initially unresponsive to IM (Imatinib), resistance develops within a few months, or blast crisis occurs early and unexpectedly following an initial response.

Status
Recruiting
Principal Investigator
Donna Forrest
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI (COMPLETE)

To determine whether, on a background of optimal medical therapy, including ticagrelor, opening of all suitable narrowings or blockages found at the time of primary PCI for an acute heart attack is better than treating only the culprit lesion in patients with multi-vessel disease.

Status
Recruiting
Principal Investigator
David Wood
Body Locations and Systems
Heart Attack
Area
Vancouver
Age
All ages

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)

Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased quality of life. Prevention is the most effective way to decrease the complications associated with blood clots in the veins.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood Clots
Area
Vancouver
Age
18 and above

Perioperative Anticoagulant Use for Surgery Evaluation Study (PAUSE)

The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a novel oral anticoagulant (NOAC) drug, either dabigatran, rivaroxaban or apixaban, and require an elective surgery/procedure.


 

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Atrial Fibrillation
Area
Vancouver
Age
18 and above

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure (ADVENT-HF)

Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these risks. This study is looking at whether a respiratory device known as Adaptive Servo Ventilation (ASV) can reduce the rate of cardiovascular hospitalizations and death in subjects with HF and SA.

Status
Recruiting
Principal Investigator
John Fleetham
Body Locations and Systems
Heart Failure
Sleep Apnea Syndromes
Area
Vancouver
Age
18 and above

Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

A randomized, double-blind placebo controlled study to determine the safety and efficacy of Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in patients treated with standard of care and with no surgical revascularization option. It is assumed that the ACP-treated group will have a lower amputation and death rate as compared to the placebo group. Other hemodynamic, imaging and clinical parameters will also be compared between the two groups. Quality of life assessments will also be performed.

Status
Recruiting
Principal Investigator
York Hsiang
Body Locations and Systems
Peripheral Arterial Disease
Area
Vancouver
Age
18 and above

Pagination

  • Previous page
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page
Subscribe to Blood, Heart and Circulation

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy